Results 1 to 10 of about 1,117,895 (256)
Objective response rate of placebo in randomized controlled trials of anticancer medicinesResearch in context [PDF]
EClinicalMedicine, 2023 Summary: Background: Spontaneous regression of advanced solid tumors is infrequent but may occur. Quantifying response rates from placebo in cancer drug trials may provide important information for physicians, patients, and regulators.
Arushi Sachdev +4 more
doaj +5 more sources
Neoadjuvant Therapy in Lung Cancer: What Is Most Important: Objective Response Rate or Major Pathological Response? [PDF]
Current Oncology, 2021 Lung cancer is the most fatal and frequently diagnosed malignant tumor. Neoadjuvant therapy is a promising approach for prolonging survival and increasing the chance of cure rates for patients with potentially resectable disease.
Xi Chen, Kewei Ma
doaj +5 more sources
Pemetrexed-based first-line chemotherapy had particularly prominent objective response rate for advanced NSCLC: A network meta-analysis [PDF]
Open Medicine, 2021 The aim of the present work was to investigate the clinical efficacy of first-line chemotherapy regimens in the treatment of advanced non-small cell lung cancer (NSCLC) through a comprehensive network meta-analysis (NMA).
Lv Yuankai +5 more
doaj +2 more sources
ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial [PDF]
npj Precision OncologyPatients with recurrent platinum-resistant ovarian cancer (PROC) have poor clinical outcomes, owing mainly to the presence of therapy-resistant cancer stem cells (CSCs).
Thomas J. Herzog +13 more
doaj +2 more sources
Frontiers in Medicine, 2023 IntroductionNRAS mutations are common in melanoma and confer a worse prognosis. Although most patients with metastatic melanoma receive immune checkpoint inhibitors (ICIs), the impact of NRAS mutational status on their efficacy remains under debate ...
Zachary J. Jaeger +8 more
doaj +1 more source
Clinical benefit and safety associated with mRNA vaccines for advanced solid tumors: A meta‐analysis
MedComm, 2023 Tumor mRNA vaccines have been developed for over 20 years. Whether mRNA vaccines could promote a clinical benefit to advanced cancer patients is highly unknown. PubMed and Embase were retrieved from January 1, 2000 to January 4, 2023.
Tian‐yi Zhang +8 more
doaj +1 more source
Efficacy and safety of olaparib in advanced ovarian cancer: a meta-analysis
Journal of Obstetrics and Gynaecology, 2023 This study aimed to evaluate the efficacy and safety of olaparib for the treatment of advanced ovarian cancer. All studies that assessed the efficacy and safety of olaparib in advanced ovarian cancer were searched in PubMed, Embase, and Web of Science ...
Yuanyuan Yang +4 more
doaj +1 more source
Frontiers in Medicine, 2023 PurposeTo compare the effectiveness and safety of drug-eluting bead bronchial artery chemoembolization (DEB-BACE) with conventional bronchial artery chemoembolization (cBACE) and provide a novel treatment option for advanced non-small cell lung cancer ...
Guocan Yu +4 more
doaj +1 more source
Frontiers in Immunology, 2021 ObjectiveTo evaluate whether the combination of immune checkpoint inhibitor (ICI) with chemotherapy is more effective than ICI alone in the treatment of recurrent, locoregionally advanced, unresectable nasopharyngeal carcinoma (RAU-NPC), which has ...
Xin Zhou +13 more
doaj +1 more source
Cancer Medicine, 2023 Background Dysbiosis of the gut microbiota can lead to impaired therapeutic effect of immune checkpoint inhibitors (ICIs). This study aimed to investigate the use of probiotics on the clinical outcomes of cancer patients receiving ICIs therapy.
Luying Wan +5 more
doaj +1 more source